This study analysed the utilization of ibrutinib, a BTK inhibitor, in treating chronic lymphocytic leukemia in Australia. It compared real-world data from the Pharmaceutical Benefits Scheme (PBS) to the RESONATE clinical trial, providing insights into ibrutinib use in the general...